regenerative-and-precision-medicine-2016_tracks

5 / 13

Notes:
Page 29
Regenerative & Precision Medicine 2016
December 1-2, 2016
Volume 7, Issue 3(Suppl) J Tissue Sci Eng
ISSN: 2157-7552 JTSE, an open access journal
conferenceseries .com
December 1-2, 2016 | San Antonio, USA
Global Congress on
Tissue Engineering, Regenerative &
Precision Medicine
Wael Abo Elkheir, J Tissue Sci Eng 2016, 7:3(Suppl)
Allogenic bone marrow-derived mesenchymal stem therapy in Duchenne muscular dystrophy
Wael Abo Elkheir
Military Medical Academy, Egypt
Background: Duchenne muscular dystrophy (DMD) is the commonest hereditary muscular dystrophy. It is characterized by
progressive muscle leading loss of walking ability and complete wheelchair dependence. Further, disability leads to respiratory
failure, which is the common cause of death.
Aim: The aimof the present work is to evaluate the safety and therapeutic efficacy of allogenic bonemarrowderivedmesenhymal
stem cell therapy in Duchenne muscular dystrophy
Subjects &Methods:This study was conducted on 40 myopathic patients, ages ranging from 6-18 years. DMDwas documented
by family history, history of disease progression, laboratory investigations, muscle biopsy and genetic study. Patients with
fixed deformities were excluded. The study group was randomly divided into patient and control groups. Both groups were
given traditional treatment (physiotherapy & medical treatment drugs); while the patient group received additionally stem
cell treatment. Stem cells were administered in 6 doses 4 weeks apart in a dose of 3×106 cells/kg suspended in 50 ml PBS. Cell
suspension was injected locally in 0.5 ml doses intramuscularly. A single systemic injection in a dose of 3 X10 6 cells/kg was
given with the sixth intramuscular dose. Follow-up was done using North Star Ambulatory Assessment CHAQ (Child Health
Assessment Questionnaire), manual muscle strength testing using Medical Research Council strength scores and functional
outcome measures. Scoring was done before and after every month for 12 months. Any complications or adverse effect were
recorded.
Results & Conclusions: During the one year follow-up, no serious complications were recorded. Self-limited pain and mild
fever were reported for 48 hours after injection. Significant improvement in assessment scores and quality of life questionnaire
was seen in the treatment group. This was translated into substantial improvement in ambulation.
Biography
Wael Abo Elkheir has completed his PhD from Cairo University, Egypt. He is the Co-Founder and Board Member of the Egyptian Society for Progenitor Stem Cell
Research, a society initiated with the mission of enhancing scientific research and cooperation in the field of stem cell research and regenerative medicine. He is the
Director of a number of registered clinical trials in the field of stem cell therapy, especially for neuro-regeneration and musculoskeletal disorders. He has published
more than 20 papers in reputed journals.